Assertio Therapeutics Company Insiders

ASRT Stock  USD 11.48  0.35  3.14%   
Assertio Therapeutics' insiders are aggressively buying. The analysis of insiders' sentiment of trading Assertio Therapeutics stock suggests that vertually all insiders are extremely bullish at this time. Assertio Therapeutics employs about 58 people. The company is managed by 13 executives with a total tenure of roughly 136 years, averaging almost 10.0 years of service per executive, having 4.46 employees per reported executive.

Insider Sentiment 100

 Aggressively Buying

 
Selling
 
Buying

Latest Trades

2024-11-18Heather L MasonAcquired 75000 @ 0.8View
2024-11-14Brendan P O'gradyAcquired 11706 @ 0.85View
Monitoring Assertio Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.

Assertio Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Assertio Therapeutics' future performance. Based on our forecasts, it is anticipated that Assertio will maintain a workforce of slightly above 60 employees by February 2026.
 
Covid

Assertio Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0417) % which means that it has lost $0.0417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2448) %, meaning that it created substantial loss on money invested by shareholders. Assertio Therapeutics' management efficiency ratios could be used to measure how well Assertio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2026. Return On Capital Employed is likely to drop to -0.14 in 2026. Liabilities And Stockholders Equity is likely to gain to about 335.7 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 74.2 M in 2026.
Common Stock Shares Outstanding is likely to gain to about 7.7 M in 2026. Net Income Applicable To Common Shares is likely to gain to about 103.6 M in 2026
The market capitalization of Assertio Therapeutics is $73.66 Million. Almost 70.24 percent of Assertio Therapeutics outstanding shares are held by general public with 2.49 (percent) owned by insiders and only 27.27 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
1997-03-31
Previous Quarter
6.4 M
Current Value
7.1 M
Avarage Shares Outstanding
2.4 M
Quarterly Volatility
4.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Dividends Paid is likely to gain to about 233 K in 2026. Dividend Paid And Capex Coverage Ratio is likely to gain to 95.38 in 2026. Common Stock Shares Outstanding is likely to gain to about 7.7 M in 2026. Net Income Applicable To Common Shares is likely to gain to about 103.6 M in 2026.

Assertio Therapeutics Workforce Comparison

Assertio Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,235. Assertio Therapeutics holds roughly 58.0 in number of employees claiming about 5% of equities under Health Care industry.

Assertio Therapeutics Profit Margins

The company has Profit Margin (PM) of (0.21) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.30.79
Way Up
Pretty Stable

Assertio Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assertio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assertio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Assertio Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-12-01
2.0
2
1
 1,500,000 
 8,959 
2025-06-01
1.75
14
8
 955,591 
 378,770 
2025-03-01
1.3333
16
12
 2,433,596 
 181,055 
2024-12-01
2.5
5
2
 241,085 
 27,999 
2024-06-01
2.4286
17
7
 3,123,926 
 283,273 
2024-03-01
1.0
13
13
 1,891,088 
 240,173 
2023-12-01
1.5
3
2
 223,282 
 28,000 
2023-09-01
0.5
4
8
 99,549 
 405,226 
2023-06-01
0.7273
16
22
 1,406,178 
 2,300,749 
2023-03-01
1.0714
15
14
 1,105,465 
 455,847 
2022-12-01
0.5
1
2
 19,404 
 26,609 
2022-09-01
0.3333
1
3
 7,135 
 13,586 
2022-06-01
2.0
8
4
 1,168,844 
 127,874 
2022-03-01
0.45
9
20
 345,439 
 744,326 
2021-12-01
2.0
4
2
 1,407,089 
 2,653 
2021-09-01
0.5
3
6
 11,418 
 14,672 
2021-06-01
2.6667
8
3
 1,487,401 
 38,032 
2021-03-01
0.4286
6
14
 2,011,505 
 1,369,143 
2020-12-01
0.3333
3
9
 116,747 
 11,386,823 
2020-09-01
0.6
3
5
 61,783 
 65,719 
2020-06-01
5.0
20
4
 4,884,993 
 56,070 
2020-03-01
0.8571
6
7
 1,566,208 
 263,936 
2019-12-01
1.5
3
2
 73,760 
 45,073 
2019-06-01
1.25
10
8
 339,956 
 201,554 
2019-03-01
2.6667
8
3
 552,216 
 81,327 
2018-12-01
0.5
2
4
 49,861 
 68,497 

Assertio Therapeutics Notable Stakeholders

An Assertio Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Assertio Therapeutics often face trade-offs trying to please all of them. Assertio Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Assertio Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark ReisenauerCEO DirectorProfile
Brendan OGradyCEO DirectorProfile
Ajay PatelExecutive CFOProfile
Heather MasonInterim DirectorProfile
Jack HoblitzellVP OperationsProfile
Sam SchlessingerExecutive CounselProfile
MD MBASenior MedicalProfile
Molly DirSenior AdministrationProfile
Bill IskosSenior OperationsProfile
Paul SchwichtenbergExecutive OfficerProfile
Jeff ChristensenSenior CommercialProfile
Mary PietrygaExecutive OfficerProfile
Daniel PeisertCEO PresProfile
String symbol = request.getParameter("s");

About Assertio Therapeutics Management Performance

The success or failure of an entity such as Assertio Therapeutics often depends on how effective the management is. Assertio Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Assertio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Assertio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.10)(0.10)
Return On Capital Employed(0.13)(0.14)
Return On Assets(0.07)(0.07)
Return On Equity(0.20)(0.19)
Please note, the imprecision that can be found in Assertio Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Assertio Therapeutics. Check Assertio Therapeutics' Beneish M Score to see the likelihood of Assertio Therapeutics' management manipulating its earnings.

Assertio Therapeutics Workforce Analysis

Traditionally, organizations such as Assertio Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Assertio Therapeutics within its industry.

Assertio Therapeutics Manpower Efficiency

Return on Assertio Therapeutics Manpower

Revenue Per Employee2.2M
Revenue Per Executive9.6M
Net Loss Per Employee372.1K
Net Loss Per Executive1.7M
Working Capital Per Employee1.5M
Working Capital Per Executive6.8M

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.